Potential role of ADAMTS13 in the progression of alcoholic hepatitis

Masahito Uemura1, Yoshihiro Fujimura, Tomomi Matsuyama

  • 1Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, 634-8522, Japan. muemura@naramed-u.ac.jp

Insights

Severe alcoholic hepatitis (SAH) involves multiorgan failure. Low ADAMTS13 activity and increased von Willebrand factor may drive microcirculatory issues in alcoholic liver injury, suggesting new therapeutic targets.

Area of Science:

  • Hepatology
  • Hematology
  • Pathophysiology

Background:

  • Alcoholic hepatitis (AH) and severe alcoholic hepatitis (SAH) are life-threatening conditions linked to alcohol abuse.
  • SAH involves multiorgan failure (MOF) and high mortality, with unclear pathogenesis.
  • ADAMTS13 (a disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13) deficiency is linked to thrombotic thrombocytopenic purpura and microcirculatory disturbances.

Purpose of the Study:

  • To investigate the role of ADAMTS13 activity and its substrate in the pathogenesis of severe alcoholic hepatitis (SAH).
  • To explore the potential link between ADAMTS13 deficiency, von Willebrand factor accumulation, and microcirculatory disturbances in alcoholic liver injury.

Main Methods:

  • Analysis of plasma ADAMTS13 activity (ADAMTS13:AC) and unusually large von Willebrand factor multimers (UL-VWFM) in patients with SAH.
  • Immunological studies and in situ hybridization to determine ADAMTS13 production sites (hepatic stellate cells - HSCs).
  • Assessment of the imbalance between ADAMTS13:AC and VWF:Ag in AH patients.

Main Results:

  • Plasma ADAMTS13:AC was extremely low in fatal SAH cases.
  • Enhanced UL-VWFM production was observed in conjunction with deficient ADAMTS13:AC.
  • Potential involvement of sinusoidal microcirculatory disturbances due to ADAMTS13:AC and VWF:Ag imbalance in AH.

Conclusions:

  • Deficient ADAMTS13:AC and increased UL-VWFM may contribute to MOF progression in SAH and AH via microcirculatory disturbances.
  • Further research is needed to clarify the mechanisms of decreased ADAMTS13:AC and its link to pro-inflammatory cytokinemia and HSC function.
  • Determining ADAMTS13:AC and its substrate could offer new insights into alcoholic liver injury pathophysiology and therapeutic strategies.

Related Concept Videos

Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
Chronic Pancreatitis I: Introduction01:25

Chronic Pancreatitis I: Introduction

Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80% of...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...